Ryan Morgan, DO
Internal Medicine · Oklahoma City, OKNPI 1033454616
Payments from drug & device makers
Across 477 payments — averaging $1624.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$239K
- AbbVie$151K
- Rhythm Pharmaceuticals, Inc.$150K
- Kedplasma LLC$145K
- Lilly USA, LLC$67K
- Boehringer Ingelheim International GmbH$16K
- plus $8K from 20 others
Across 16 payments — averaging $116.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 15 | $238,681 |
| AbbVie(2 entities) | 39 | $150,905 |
| Rhythm Pharmaceuticals, Inc. | 55 | $149,527 |
| Kedplasma LLC | 45 | $145,000 |
| Lilly USA, LLC | 129 | $66,952 |
| Boehringer Ingelheim International GmbH | 83 | $15,644 |
| Novo Nordisk | 45 | $3,841 |
| Madrigal Pharmaceuticals | 12 | $2,170 |
| Amgen | 22 | $777 |
| Novartis | 7 | $220 |
| Echosens North America, Inc. | 2 | $177 |
| Dexcom, Inc. | 2 | $173 |
| Esperion Therapeutics, Inc. | 3 | $153 |
| Regeneron Healthcare Solutions, Inc. | 2 | $130 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Medicure Pharma Inc. | 1 | $122 |
| Althera Pharmaceuticals LLC | 1 | $105 |
| Corcept Therapeutics | 4 | $88 |
| Reshape Lifesciences Inc. | 1 | $47 |
| Bayer | 2 | $42 |
| AstraZeneca | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$774,973 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Oklahoma City
- Sagila GeorgeOklahoma City$1.8M
- Samid FarooquiOklahoma City$129K
- Minh PhanOklahoma City$77K
- Ali JafryOklahoma City$33K
- Stuart SchraderOklahoma City$29K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.